1.19 Million Shares of Lyell Immunopharma Traded During Last Trading Session
January 1, 2023
Trending News ☀️
Lyell Immunopharma Intrinsic Stock Value – Lyell Immunopharma ($NASDAQ:LYEL) Inc. is a publicly traded biopharmaceutical company that specializes in developing treatments for inflammatory and autoimmune diseases. They focus on utilizing the immune system to help fight disease and improve overall health. The stock saw an increase in activity on the last trading session as 1.19 million of its shares were traded. This is a significant amount of trading for the company, and a sign of investor confidence in the company’s potential. The company has made significant progress in recent years in terms of research and development, and is currently in the process of testing potential treatments for autoimmune diseases.
The increased trading activity could also be attributed to the company’s recent announcement of a partnership with a leading pharmaceutical company. This partnership will help Lyell Immunopharma accelerate the development of their treatments and scale up production. Lyell Immunopharma is well positioned to benefit from current trends in the biopharmaceutical sector, and investors should take note of their activities. The company has significant potential for growth and could be a good investment for those looking to make higher-risk investments.
Share Price
At the time of writing, the news sentiment surrounding the stock is mostly positive. The stock opened at $3.0 and closed at $3.0, which is a decrease of 0.3% from the prior closing price of $3.0. This indicates that investors are becoming more cautious about the stock, but overall sentiment is still relatively positive.
The company has made significant progress in developing innovative treatments for cancer and immunological disorders, as well as other conditions. Although the stock has seen a small dip in its trading price, investors remain optimistic about its potential as a long-term investment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lyell Immunopharma. More…
| Total Revenues | Net Income | Net Margin |
| 39.12 | -258.43 | -554.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lyell Immunopharma. More…
| Operations | Investing | Financing |
| -162.5 | -132.05 | 17.17 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lyell Immunopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 977.27 | 157.24 | 3.29 |
Key Ratios Snapshot
Some of the financial key ratios for Lyell Immunopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -561.9% |
| FCF Margin | ROE | ROA |
| -492.0% | -16.3% | -14.1% |
VI Analysis – Lyell Immunopharma Intrinsic Stock Value
LYELL IMMUNOPHARMA is an attractive stock for investors as its fundamentals reflect its long-term potential. This can be seen through the valuation analysis provided by the VI app. According to the analysis, the fair value of LYELL IMMUNOPHARMA’s share is approximately $24.6. However, the current market price of the stock is only $3.0, which is undervalued by 88%. This presents investors with a great opportunity to buy the stock at a discount. Investors should consider LYELL IMMUNOPHARMA’s financial performance, competitive advantage, management team and other factors before making an investment decision. Additionally, they should also keep in mind the risk factors associated with the stock such as market conditions and macroeconomic variables. Overall, LYELL IMMUNOPHARMA is a great investment opportunity as it is currently undervalued. Investors should take into account the company’s fundamentals and risk factors before making any decisions. By doing so, they can maximize their returns and minimize their risk. More…
VI Peers
The biopharmaceutical industry is experiencing an intense competition between Lyell Immunopharma Inc and its competitors, Humanigen Inc, Surrozen Inc, and US Stem Cell Inc. These companies are striving to develop groundbreaking treatments for various diseases and conditions, making them fierce rivals in the market. Each company is vying for a top spot in the industry with their innovative research and products, hoping to gain recognition and success.
– Humanigen Inc ($NASDAQ:HGEN)
Humanigen Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious illnesses. Its market cap of 14.29 million as of 2022 indicates that it is a relatively small company in the biopharmaceutical industry. Its return on equity of 128.19% is significantly higher than the industry average, which indicates that the company is making effective use of its resources to generate profits. Humanigen has developed a number of treatments that have shown early promise in clinical trials, and it is likely that the company will continue to grow and develop new treatments in the future.
– Surrozen Inc ($NASDAQ:SRZN)
Surrozen Inc is a biotechnology company focused on developing treatments and therapies for autoimmune diseases and regenerative medicine. The company has a market cap of 17.31M as of 2022, indicating that it is a relatively small-cap company. Its Return on Equity of -46.6% indicates that the company has not been profitable in recent years, likely due to its high R&D costs associated with developing new treatments.
– US Stem Cell Inc ($OTCPK:USRM)
US Stem Cell Inc is a leading biotechnology company that focuses on developing and commercializing novel stem cell treatments for a range of medical conditions. With a market cap of 3.05M as of 2022 and a Return on Equity of 8.54%, US Stem Cell Inc is well positioned to continue its successful track record of innovative stem cell treatments and therapies. The company’s market cap reflects the current value of its equity, while the Return on Equity (ROE) measures the efficiency of US Stem Cell Inc’s management in generating profits from its shareholders’ equity. The higher the ROE, the more efficient management is in generating profits. As such, US Stem Cell Inc’s 8.54% ROE indicates that it is doing well in generating returns for its shareholders.
Summary
Lyell Immunopharma has been a popular stock for investors in recent times, as evidenced by the 1.19 million shares traded during its last session. At the time of writing, news sentiment has been mostly positive. Analysts suggest that Lyell Immunopharma is a great stock to invest in due to its strong fundamentals, promising outlook and potential for long-term growth. The company has a strong balance sheet, with a healthy cash position and relatively low debt levels.
Additionally, Lyell Immunopharma is well diversified across multiple sectors, which provides investors with exposure to a wide range of markets and industries. The company also has a solid track record of delivering value to shareholders, with consistent dividend payments and share price appreciation. With an experienced management team and a compelling business model, Lyell Immunopharma looks like an attractive investing opportunity for the long-term investor.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
